The Vienna Prograf and Endothelial Progenitor Cell Study
NCT00182559
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
148
Enrollment
OTHER
Sponsor class
Conditions
End Stage Renal Disease
Interventions
DRUG:
Ciclosporin
DRUG:
Tacrolimus
Sponsor
Medical University of Vienna